MMP1 is also linked to resistance in erlotinib-treated non-small cell lung cancer (NSCLC), where its high expression correlates with poor survival outcomes, suggesting it as a marker of erlotinib resistance [35]. This evidence concerns the gene MMP1 and non-small cell lung carcinoma.